Abstract
Periodontal diseases are localized, plaque‐related infections. Often, clinical signs of inflammation are not eradicated by supragingival plaque control, dictating that subgingival microbial populations must be reduced. Confirmation that it is possible to deliver medicaments to the base of deep pockets stimulated numerous investigations. This report evaluates the role of site‐specific pharmacotherapy to enhance periodontal status.